Holen Sie sich die Stockscreener-App
23.87
4.88%
-1.25
Schlusskurs vom Vortag:
$25.12
Offen:
$25.15
24-Stunden-Volumen:
1.45M
Relative Volume:
0.93
Marktkapitalisierung:
$1.35B
Einnahmen:
$308.05M
Nettoeinkommen (Verlust:
$-95.57M
KGV:
-13.88
EPS:
-1.72
Netto-Cashflow:
$-58.34M
1W Leistung:
-6.48%
1M Leistung:
-1.34%
6M Leistung:
-32.19%
1J Leistung:
-53.36%
1-Tages-Spanne:
$23.76
$25.61
1-Wochen-Bereich:
$23.76
$26.39
52-Wochen-Spanne:
$19.35
$66.85
Procept Biorobotics Corp Stock (PRCT) Company Profile
Firmenname
Procept Biorobotics Corp
Sektor
Branche
Telefon
(650) 232-9832
Adresse
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
23.86 | 1.42B | 308.05M | -95.57M | -58.34M | -1.72 |
ABT
Abbott Laboratories
|
102.04 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.89 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.23 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.50 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.03 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Eingeleitet | Robert W. Baird | Neutral |
| 2026-02-26 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-26 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-12-12 | Eingeleitet | UBS | Buy |
| 2025-12-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-09 | Eingeleitet | Stephens | Overweight |
| 2025-07-07 | Eingeleitet | Oppenheimer | Perform |
| 2024-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Eingeleitet | Jefferies | Hold |
| 2023-08-11 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-31 | Eingeleitet | William Blair | Outperform |
| 2022-10-31 | Eingeleitet | BTIG Research | Neutral |
| 2022-10-25 | Eingeleitet | Truist | Buy |
| 2022-09-02 | Eingeleitet | Wells Fargo | Overweight |
| 2022-07-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Goldman | Neutral |
| 2021-10-11 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Procept Biorobotics Corp Aktie (PRCT) Neueste Nachrichten
Morgan Stanley Maintains PROCEPT BioRobotics (PRCT) Overweight Recommendation - MSN
Oppenheimer Upgrades PROCEPT BioRobotics (PRCT) - MSN
A Look At PROCEPT BioRobotics (PRCT) Valuation After New European Aquablation Guideline Upgrade - simplywall.st
PRCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Aquablation’s Strong EU Guideline Backing Reshape PROCEPT BioRobotics’ (PRCT) Long-Term Narrative? - Sahm
Prosight Management, LP's PROCEPT BioRobotics Corp(PRCT) Holding History - gurufocus.com
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES - MarketScreener
PROCEPT BioRobotics (PRCT) strengthens its case with expanding system base - MSN
Short Covering: Is PROCEPT BioRobotics Corporation a turnaround story2026 Patterns & Real-Time Buy Signal Alerts - baoquankhu1.vn
PROCEPT BioRobotics: An Undervalued Surgical Robotics Growth Story (NASDAQ:PRCT) - Seeking Alpha
PROCEPT BioRobotics (PRCT) price target decreased by 37.60% to 33.58 - msn.com
Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating - MSN
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Hold" by Brokerages - MarketBeat
PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 6.6%Still a Buy? - MarketBeat
Vanguard Realigns Reporting; PROCEPT BioRobotics (PRCT) Beneficial Ownership 0% - Stock Titan
EAU Upgrade Puts Aquablation And PROCEPT BioRobotics In Focus - Yahoo Finance
PROCEPT BioRobotics (PRCT) Strengthens Its Case with Expanding System Base - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics CorporationPRCT - prnewswire.com
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES - GlobeNewswire
How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation - simplywall.st
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion - MSN
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
JPMorgan Chase & Co. Cuts Stake in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating PROCEPT BioRobotics Corporation (PRCT) And Encourages Shareholders to Connect - ACCESS Newswire
A Look At PROCEPT BioRobotics (PRCT) Valuation After Aquablation Wins Strong European Guideline Backing - simplywall.st
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT) - The Globe and Mail
Europe's top urology guide strongly backs Aquablation for BPH - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PROCEPT BioRobotics Corporation (PRCT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Top Executive Quietly Unloads PROCEPT BioRobotics Shares in Notable Insider Move - TipRanks
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock - Investing.com India
Waters Kevin, EVP, CFO of Procept Biorobotics, sells $19,876 in PRCT - Investing.com India
Insider Sell: Alaleh Nouri Sells Shares of PROCEPT BioRobotics C - GuruFocus
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock By Investing.com - Investing.com Australia
PROCEPT BioRobotics (NASDAQ:PRCT) EVP Sells $139,223.48 in Stock - MarketBeat
PROCEPT BioRobotics (NASDAQ:PRCT) EVP Kevin Waters Sells 706 Shares - MarketBeat
PROCEPT BioRobotics (NASDAQ: PRCT) EVP completes 5,363-share planned sale - Stock Titan
Nouri, Procept EVP, CLO, sold $8.6k in PRCT stock - Investing.com
Alalah Nouri (NASDAQ: PRCT) files Form 144 to sell vested RSUs - Stock Titan
PROCEPT BioRobotics (PRCT) CLO sells 304 shares to cover RSU taxes - Stock Titan
PROCEPT (NASDAQ: PRCT) CFO sells 706 shares for tax withholding - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PROCEPT BioRobotics Corporation (PRCT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating PROCEPT BioRobotics Corporation (PRCT) And Encourages Investors to Connect - ACCESS Newswire
PRCT (NASDAQ) insider sale of 6,892 shares; 304 restricted shares vested - Stock Titan
Restricted stock vesting notice at PRCT (NASDAQ: PRCT) with prior insider sale - Stock Titan
Finanzdaten der Procept Biorobotics Corp-Aktie (PRCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):